MarketCap
Facebook
X
Telegram
Y-mAbs Therapeutics Balance Sheet 2024-2011 | YMAB
Brief overview of Y-mAbs Therapeutics's assets and capital
The balance sheet is assessed across five available annual reports spanning 2020 to 2024.
Across five reporting periods, assets decreased -9.2%, from $132 million to $119.9 million, producing a negative trend.
Asset growth of -9.2% came with a +6.4% rise in liabilities. Financial leverage became more prominent.
Equity accounts for 76.7% of assets. Against the initial 80.2%, the capital position looks resilient.
Net debt moved below zero to -$66.4 million, reflecting surplus cash over debt.
Cash equals 56.1% of the balance sheet, compared with 86.8% five periods ago. This is the readily available cushion.
The balance sheet includes a negative accumulated result of -$487.1 million. It should be assessed alongside historical profits and capital distributions.
Overall picture
Taken together, the figures indicate acceptable resilience for Y-mAbs Therapeutics. The next assessment depends on debt and equity trends.
Annual Balance Sheet Y-mAbs Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-66.4 M | -77.2 M | -104 M | -178 M | -111 M | -205 M | -148 M | -90.5 M | -16.9 M | - | - | - | - | - |
Long Term Debt |
190 K | 517 K | 899 K | 1.85 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
630 K | 902 K | 868 K | 1.78 M | 1.97 M | 516 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 6.68 M | 3.88 M | 2.27 M | 2.05 M | 2.22 M | - | - | - | - | - |
Total Current Liabilities |
23.7 M | 20.1 M | 28.3 M | 27.9 M | 19.5 M | 13.6 M | 9.12 M | - | - | - | - | - | - | - |
Total Liabilities |
27.9 M | 26.9 M | 32.2 M | 32.7 M | 26.2 M | 17.5 M | 11.4 M | 9.98 M | 5.2 M | - | - | - | - | - |
Retained Earnings |
-487 M | -457 M | -436 M | -340 M | -285 M | -166 M | -84.8 M | -41.6 M | -22.4 M | - | - | - | - | - |
Total Assets |
120 M | 128 M | 141 M | 213 M | 132 M | 216 M | 152 M | 92.1 M | 17.3 M | - | - | - | - | - |
Cash and Cash Equivalents |
67.2 M | 78.6 M | 106 M | 182 M | 115 M | 207 M | 148 M | 90.5 M | - | - | - | - | - | - |
Book Value |
92 M | 101 M | 109 M | 180 M | 106 M | 199 M | 141 M | 82.2 M | 12.1 M | - | - | - | - | - |
Total Shareholders Equity |
92 M | 101 M | 109 M | 180 M | 106 M | 199 M | 141 M | 82.2 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Y-mAbs Therapeutics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
2.64 M | 148 K | 190 K | 299 K | 432 K | 293 K | 517 K | 725 K | 416 K | 629 K | 899 K | 1.02 M | 1.3 M | 1.6 M | 1.85 M | 654 K | 988 K | 1.52 M | 2.01 M | 2.01 M | 2.01 M | 2.01 M | 1.71 M | 1.71 M | 1.71 M | 1.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
29.7 M | 23.2 M | 27.9 M | 28.5 M | 48.7 M | 24.1 M | 26.9 M | 28.7 M | 27.7 M | 29.6 M | 32.2 M | 36 M | 33.8 M | 33.6 M | 32.7 M | 29.1 M | 25.2 M | 22.7 M | 26.2 M | 26.2 M | 26.2 M | 26.2 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M | 11.4 M | 11.4 M | 11.4 M | 11.4 M | 9.98 M | 9.98 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-496 M | -492 M | -487 M | -480 M | -473 M | -464 M | -457 M | -456 M | -449 M | -442 M | -436 M | -437 M | -410 M | -369 M | -340 M | -304 M | -275 M | -252 M | -285 M | -285 M | -285 M | -285 M | -166 M | -166 M | -166 M | -166 M | -84.8 M | -84.8 M | -84.8 M | -84.8 M | -41.6 M | -41.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
117 M | 113 M | 120 M | 121 M | 144 M | 123 M | 128 M | 129 M | 132 M | 137 M | 141 M | 144 M | 165 M | 191 M | 213 M | 240 M | 259 M | 275 M | 132 M | 132 M | 132 M | 132 M | 216 M | 216 M | 216 M | 216 M | 152 M | 152 M | 152 M | 152 M | 92.1 M | 92.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
62.3 M | 60.3 M | 67.2 M | 68.1 M | 77.8 M | 75.7 M | 78.6 M | 86.6 M | 87.9 M | 92.6 M | 106 M | 115 M | 134 M | 157 M | 182 M | 216 M | 234 M | 252 M | 115 M | 115 M | 115 M | 115 M | 207 M | 207 M | 207 M | 207 M | 148 M | 148 M | 148 M | 148 M | 90.5 M | 90.5 M | - | - | 16.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
87.5 M | 89.5 M | 92 M | 92.4 M | 95.3 M | 99.2 M | 101 M | 100 M | 105 M | 108 M | 109 M | 108 M | 131 M | 157 M | 180 M | 211 M | 234 M | 252 M | 106 M | 106 M | 106 M | 106 M | 199 M | 199 M | 199 M | 199 M | 141 M | 141 M | 141 M | 141 M | 82.2 M | 82.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
87.5 M | 89.5 M | 92 M | 92.4 M | 95.3 M | 99.2 M | 101 M | 100 M | 105 M | 108 M | 109 M | 108 M | 131 M | 157 M | 180 M | 211 M | 234 M | 252 M | 106 M | 106 M | 106 M | 106 M | 199 M | 199 M | 199 M | 199 M | 141 M | 141 M | 141 M | 141 M | 82.2 M | 82.2 M | - | - | 12.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Y-mAbs Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
